

From Sequence Design to AOC Production Medication's End-to-End RNAi Development Platform

Aoqiang¹, Binbin¹, Maosheng Du¹, Binbin¹, Hengyu Song¹, Jingcong Li¹, and Steven Han¹
¹ Shanghai Medicilon Inc., Chuanda Road, Shanghai 01, China; Medicilon USA Corp., 00 Med

Anchored to a sophisticated RNAi platform, our AOC capabilities are supported by a vertically integrated expertise spanning sequence design, nucleotide synthesis, and in vivo eval

Medication Optimal Design (MOD)

Mono-Nucleotide

Oligonucleotide Synthesis

Delivery & Carriers